Risk stratification in therapy-related myelodysplastic syndromes
Oncotarget
.
2017 Sep 24;8(46):80103-80104.
doi: 10.18632/oncotarget.21178.
eCollection 2017 Oct 6.
Author
Amer M Zeidan
1
Affiliation
1
Section of Hematology, Department of Internal Medicine, Yale University, and Yale Comprehensive Cancer Center, New Haven, CT, USA.
PMID:
29113285
PMCID:
PMC5655180
DOI:
10.18632/oncotarget.21178
No abstract available
Keywords:
myelodysplastic syndromes; prognostic tools; therapy-related.
Publication types
Editorial
Grants and funding
UL1 TR001863/TR/NCATS NIH HHS/United States